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Abstract
Background: Hepatocellular carcinoma (HCC) accounts for 75 % of liver cancers and is the second most lethal
cancer, associated with its multiple etiologies, poor prognosis and resistance to chemotherapy drugs.
Chemotherapy treatment on HCC suffers low efficacy of drug uptake and can produce a range of side effects. Here
we report an investigation on the effect of a combined treatment on human hepatocellular carcinoma BEL-7402
cells using low-intensity ultrasound (US) and 5-fluorouracil (5-FU).
Methods: The uptake of 5-FU was measured by the high-performance liquid chromatography (HPLC). DNA
damage was detected by the comet assay. MTT assay was used to examine cell viability. Intracellular reactive
oxygen species (ROS) and mitochondrial membrane potential (Δψm) were respectively detected by the fluorescent
probes DCFH-DA or JC-1. Endogenous apoptosis-associated proteins were analyzed by the western blot and
immunohistochemistry. Histopathological changes were evaluated by the hematoxylin and eosin (H&E) staining.
Cell apoptosis was evaluated by the TUNEL and flow cytometry assays. Cell proliferation was measured using the
immunohistochemical staining of PCNA.
Results: Our results showed that low-intensity US (1.1 MHz, 1.0 W/cm2, 10 % duty cycle) significantly enhanced the
uptake of 5-FU, 5-FU-mediated DNA damage and reactive oxygen species (ROS) generation. The increased ROS
production up-regulated the p53 protein level, which led to the up-regulation of Bax and down-regulation of Bcl-2.
The enhancement of ROS generation and the activation of the apoptosis-associated proteins further triggered the
collapse of mitochondrial membrane potential, released cytochrome c from mitochondria into cytosol and
activated the mitochondria-caspase pathway, and cell apoptosis. Such enhanced effects could be partially blocked
by the ROS scavenger N-acetylcysteine (NAC). Overall, low-intensity US combined with 5-FU led to an effective
inhibition of tumor growth and prolonged overall survival of BEL-7402 HCC-bearing nude mice by more than 15 %
compared with 5-FU treatment alone.
Conclusions: Our results showed that low-intensity ultrasound combined with 5-FU produced much enhanced
synergistic anti-tumor effects via enhanced ROS production in treating HCC.
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Background
Hepatocellular carcinoma (HCC) is the sixth most
prevalent cancer and the second most lethal cancer, with
the rate of 5-year survival below 20 % [1]. Statistics show
that there were nearly 800,000 new cases worldwide in
2012 and the number increases each year [2]. The eti-
ology and pathogenesis of HCC are not yet fully eluci-
dated because of its heterogeneity and multiple causes,
but chemotherapy is a treatment modality for HCC but
the effect is not satisfactory [3]. The 5-fluorouracil (5-
FU), as an important antimetabolite and cell cycle-
targeting drug, has been widely used for the treatment
of gastric, colorectal, and breast cancers [4], and it exerts
its anti-tumor effects through the inhibition of RNA/
DNA processing and thymidylate synthase [4]. In recent
years, 5-FU proved to be beneficial in treating advanced
HCC in the FOLFOX4 regimen (including infusional 5-
FU, leucovorin, and oxaliplatin), which increased the
overall survival of HCC patients by 1.47 months [5].
However, the low efficacy of drug uptake compels doc-
tors to use higher doses of 5-FU, causing a range of side
effects, including leukopenia, nausea, emesis, and skin
reactions. Therefore, there is an urgent need to find bet-
ter ways that can improve the sensitivity of HCC to
chemotherapy, and to reduce drug-dosage so as to re-
duce side effects.
Therapeutic ultrasound (US), especially low-intensity
US, has gained increasing attention in recent years [6].
There are several important advantages of US assisted
therapies, particularly sonodynamic therapy (SDT), in
which ultrasonic waves can penetrate deep into the tissue
to stimulate sonosensitizers that are specifically localized
in the tumor to achieve localized anticancer effects [7]. In
general, US can cause both physical effects (such as heat,
cavitation, and mechanical force) and biochemical effects
(such as reactive oxygen species) to effect tumor cell dam-
age and apoptosis [8]. Some investigations demonstrated
that low-intensity US enhanced anti-tumor effects of che-
motherapeutic agents, including doxorubicin [9], cyclo-
phosphamide [10], docetaxel [11], cisplatin [12], etc. We
also demonstrated the efficacy of combined chemotherapy
on human tongue cancer cells in vitro and in vivo using
scutellarin and US, and found that the combined treat-
ment with much reduced drug dosage significantly
inhibited tumor angiogenesis, suppressed cancer cell
proliferation and induced cancer cell apoptosis [13].
The aim of this work is to determine whether low-
intensity US can promote the uptake of 5-FU by HCC
cancer cells, and to see if low-intensity US combined
with 5-FU (US + 5-FU) can effectively inhibit the growth
of BEL-7402 HCC-bearing nude mice. We will look at
the changes in the 5-FU-mediated ROS generation and





zolium bromide (MTT; 98 % purity), 2-(4-Amidinophe-
nyl)-6-indolecarbamidine dihydrochloride (DAPI; purity
by HPLC: ≥ 98 %), 5-FU (purity by HPLC: ≥ 99 %), and
N-acetylcysteine (NAC; purity by TLC: ≥ 99 %) were
purchased from Sigma-Aldrich (St Louis, MO, USA).
Mito-Tracker Green and Z-VAD-FMK were purchased
from Beyotime (Shanghai, China). Mouse anti-PCNA
(60097) was purchased from Proteintech (Chicago, IL,
USA). Mouse anti-p53 (ab26) and the rabbit anti-
cytochrome c (ab133504) were purchased from Abcam
(Cambridge, MA, USA). Rabbit anti-Bcl-2 (sc-492),
rabbit anti-Bax (sc-526) and mouse anti-β-actin (sc-
47778) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit anti-cleaved caspase-3
(9661) was obtained from Cell Signaling Technology
(Beverly, MA, USA).
Cell culture
Human hepatocellular carcinoma BEL-7402, Hep G2,
and HuH-7 cell lines were provided by China Center for
Type Culture Collection (Wuhan, Hubei, China). Cells
were incubated in Dulbecco′s modified Eagle′s medium
(DMEM) supplemented with 10 % fetal bovine serum at
37 °C in an atmosphere of 95 air and 5 % CO2.
Ultrasound device and intensity measurement
For the in vitro experiments (Fig. 1a), a 3.5 cm diam-
eter polystyrene cell culture dish (Corning, NY, USA)
with a tumor cell suspension was placed in degassed
water 8 cm above the 4.0 cm diameter ultrasonic
transducer (nonfocused, 1.1 MHz center frequency,
10 % duty cycle, 100 Hz pulse repetition frequency)
with a 2.5 cm thick aluminum transmission medium.
An ultrasonic wave absorber was fitted to the internal
surface of the acrylic sonication tank to avoid wave
reflections. The US intensity was measured using an
HNC-1000 needle-type hydrophone (0.1 cm active elem-
ent size, 1–20 MHz bandwidth) (Onda, Sunnyvale, USA).
For the in vivo experiments (Fig. 1b), a 3.0 cm diameter
nonfocused ultrasonic transducer was attached to a
tapered aluminum buffer head with a 0.5 cm diameter
front surface, which was directly in contact with
tumor site skin using acoustic couplant gel. A water-
proof thermocouple was immersed in the solution for
measuring the temperature during the in vitro experi-
ments. For the in vivo experiments, the temperature
measurements were on the skin above the tumor
under the ultrasound transducer. Due to the low in-
tensity level, the temperature increase in all experi-
ments was less than 2 °C.
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High-performance liquid chromatography (HPLC) and
measurement of drug uptake
The uptake of 5-FU was measured using an Agilent
1200 series HPLC system (Santa Clara, CA, USA). The
chromatographic conditions were as follows: the chro-
matographic column was a 20RBAX Eclipse XDB-C18
column (4.6 × 150 mm, 5 μm particle size); the mobile
phase was 10 mM phosphate-buffered saline (PBS;
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and
2 mM KH2PO4, pH 7.4); the flow rate was 1.0 ml/min;
the column temperature was 25 °∁; the detection wave-
length was at 265 nm and the injection volume was
10 μl. Briefly, cell suspensions (1 × 106) with 10 μg/ml 5-
FU were immediately sonicated and incubated for
30 min. The cells were disrupted and harvested in cold
PBS. The supernatant was injected in the column for
analysis.
Intracellular ROS detection
The detection was performed by using a Reactive Oxy-
gen Species Assay Kit (Applygen, Beijing, China). Briefly,
cells pretreated with DCFH-DA (10 μM) at 37 °C for
10 min were sonicated and examined using an Olympus
IX71 invert fluorescence microscope (Tokyo, Japan) after
20 min of incubation. The ROS production was calcu-
lated using the IPP software.
Comet assay
DNA damage was detected using the alkaline comet
assay 24 h after the different treatments as described by
He et al. [14]. The cells were stained with PI, and the tail
moment (% Tail DNA) was evaluated using a fluores-
cence microscope. The percentage of comets formed
reflected the degree of DNA damage.
Cell viability and treatment protocol
Cell viability was evaluated by the MTT assay. Cells were
treated with the following dosages of 5-FU: 0, 2, 5, 10,
20, 40, 60, 80, and 100 μg/ml. After 48 h of incubation,
cells were treated with MTT (final concentration of
0.5 mg/ml) for 4 h and shocked with 150 μl DMSO per
well for 10 min. The absorbance value was measured at
490 nm using SpectraMax M3 plate reader (Molecular
Devices, Sunnyvale, CA, USA). For the in vitro US + 5-
FU treatment, cells were divided into four groups: (1)
Control; (2) US; (3) 5-FU; (4) US + 5-FU. After 30 min
of incubation, cell suspensions with 10 μg/ml 5-FU were
immediately sonicated by US (1.1 MHz, 1 W/cm2, 10 %
duty cycle) for 5 min and drug residues were removed
using saline. After 48 h of incubation, cell viability was
measured and protein expression was analyzed by west-
ern blot. In addition, some cells were also pretreated
with NAC (5 mM) or z-VAD-FMK (10 μM) for 1 h prior
to loading 5-FU to study the ROS effects.
Mitochondrial membrane potential detection
The detection was carried out by using a Mitochondrial
Membrane Potential Detection Kit (Beyotime, Shanghai,
China). Immediately after the treatments, cells were in-
cubated with JC-1 for 20 min and examined by an
inverted fluorescence microscope. The fluorescence in-
tensities were calculated using the IPP software.
Immunofluorescence
Five hours after the treatments, cells were incubated
with 200 nM Mito-Tracker Green for 30 min. Then the
cells were blocked with 1 % BSA (dissolved in PBS and
0.05 % Tween-20) for 20 min and incubated with cyto-
chrome c antibody (1:100) overnight at 4 °C. Alexa Fluor
555 secondary antibody (1: 500; Beyotime, Shanghai,
China) was added for 1 h followed by the addition of
DAPI for 15 min. Finally, cells were examined using an
Olympus BX51 fluorescence microscope (Tokyo, Japan).
Fluorescence images of cytochrome c, Mito-Tracker
Green, and DAPI were taken at the excitation of
555 nm, 490 nm and 364 nm, respectively.
Fig. 1 Schematic diagram of low-intensity ultrasound device and the experimental setup. The tone-burst ultrasonic transducer (1.1 MHz center
frequency, 10 % duty factor, 100 Hz pulse repetition rate) for the in vitro (a) and in vivo (b) experiments
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Immunohistochemistry
As described in a previous work [15], the tissue sections
were dewaxed, rehydrated, and retrieved in 10 mM cit-
rate buffer pH 6.0 (10 mM citrate buffer and 0.05 %
Tween-20). Then these sections were immersed in 3 %
hydrogen peroxide for 15 min and stained with different
primary antibodies (1:100) with the non-immunized goat
serum at 4 °C overnight. After incubating with second-
ary antibodies (1:3000) for 30 min, the sections were
stained with DAB (Zhongshan Goldenbridge, Beijing,
China). Immunopositive cells were randomly selected
from 10 fields (magnification × 200) and calculated using
the IPP software.
Western blot
Cell lysates were prepared in RIPA buffer {50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 %
(v/v) Triton X-100, 1 % (w/v) sodium deoxycholate,
and 0.1 % (w/v) SDS} in the presence of a proteinase
inhibitor cocktail Complete mini (Roche, Indianapolis, IN,
USA), separated by 12 % SDS-PAGE, and transferred to
nitrocellulose membranes. After blocking using 5 % non-fat
dried milk with TBST buffer (10 mM Tris–HCl pH 8.0,
150 mM NaCl, and 0.05 % Tween-20), membranes were
incubated with primary antibodies-p53 (1:1000), Bcl-2
(1:500), Bax (1:500) and cleaved caspase-3 (1:1000)
overnight at 4 °C and then incubated with horseradish
peroxidase-conjugated secondary antibodies (1:5000)
for 1 h. Bands were detected using a Pro-light HRP
Chemiluminescence Kit (TIANGEN, Beijing, China).
Flow cytometry
Apoptosis evaluation was performed by using a FITC
Annexin V Apoptosis Detection Kit I (BD Biosciences,
San Diego, CA, USA). Briefly, 5 h after the treatments,
cells were suspended in 500 μl binding buffer (0.01 M
Hepes/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2)
with a mixture of 5 μl FITC Annexin V (1 μg/ml) and
5 μl PI (2 μg/ml) to incubate for 15 min. The samples
(20,000 events) were analyzed using a BD FACS Canto II
flow cytometer (San Diego, CA, USA).
Tumor treatment protocol
Six- or 8-week-old female BALB/c nude mice (about
20 g/mouse) were purchased from the SLAC Laboratory
Animal Company (Shanghai, China). BEL-7402 cells
(1 × 107) with 200 μl DMEM were subcutaneously injected
into the flanks of nude mice to make cancer models. When
the tumors reached ~100 mm3, the mice were randomly di-
vided into 12 groups with 6 mice per group for three differ-
ent experiments: (1) Screening for suitable dosages of 5-FU.
The four groups were as follows: Control, untreated control
mice; 5-FU, mice received chemotherapy treatment using 5,
10, 20 mg/kg 5-FU, respectively, by intraperitoneal
injection; (2) Evaluation of the anti-tumor efficacy. The four
groups were as follows: Control, untreated control mice;
US, mice treated with US (1.1 MHz, 1 W/cm2, 10 % duty
cycle) alone for 10 min; 5-FU, mice received 10 mg/kg 5-
FU; US + 5-FU, mice treated with US after 30 min of 5-FU
administration. The mice were euthanized after 17 days; (3)
Survival analysis. The last four groups were divided in the
same way as in (2). The mice were euthanized when they
lost 10 % of body weight to avoid artifacts. Tumor volume
and body weight were measured every 2 days. Tumor
diameter was measured using a vernier caliper and tumor
volume was calculated by the formula V = π/6 × L × S2
(here L and S are the long and short diameters, respect-
ively). All experiments were performed according to the
standards developed by the Experimental Animal Care
and Use Committee of Harbin Institute of Technology.
Hematoxylin and eosin (H&E) staining
Tumors were fixed using 10 % formalin for at least 24 h.
Samples were then paraffin-embedded, sectioned, and
stained. Histopathological changes were observed using
a light microscope.
TUNEL assay
Tumor xenografts were detected by using an In Situ Cell
Death Detection Kit (Roche, Mannheim, Germany) as
described in a previous work [16]. The apoptosis index
(AI) was evaluated by counting the number of TUNEL-
positive (brown-stained) cells in 10 randomly selected
fields (magnification × 200) and calculated the integrated
optical density (IOD) values by using an Image-Pro Plus
(IPP) software.
Statistical analysis
Survival analyses were estimated by using a SPSS software
(IBM SPSS, Armonk, NY, USA) using the Kaplan-Meier
method. Data was compared with the log-rank test and
expressed as the means ± SD. Statistical differences were
evaluated by using a one-way ANOVA Dunnett’s test.
Differences between any two groups were assessed by
the Student Newman-Keuls test, with p < 0.05 consid-
ered to be statistically significant.
Results
Low-intensity ultrasound enhanced the uptake of 5-FU
and 5-FU-mediated ROS generation
To investigate the underlying mechanism of US + 5-
FU-mediated anti-tumor effects, we measured intracel-
lular 5-FU uptake in vitro. As shown in Fig. 2a, after the
application of ultrasound, the cumulative amounts of 5-FU
in the US + 5-FU group (9.3 × 10−7 μg per cell) increased
about 7-fold compared with the 5-FU alone group
(1.3 × 10−7 μg per cell; p < 0.05), indicating that low-
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intensity US effectively increased the uptake of 5-FU in
BEL-7402 cells.
Previous studies have verified that intracellular ROS plays
a key role in 5-FU-mediated anti-tumor effects [17, 18].
Here we monitored intracellular ROS levels and found that
compared with the Control group (100 ± 21.1 %), the rela-
tive green fluorescence intensities of ROS increased 3-fold
in the US alone group (320.6 ± 50.2 %) and 7-fold in the
5-FU alone group (689.8 ± 90.2 %; Fig. 2b, c). However,
the fluorescence intensities of the US + 5-FU treatment
increased significantly by as much as 14-fold (1437.4 ±
150.7 %; p < 0.05 vs. other three NAC-untreated groups),
and these fluorescence intensities were reduced by as
much as 78.0 ± 10.3 % by the ROS scavenger NAC
(316.5 ± 66.2 %; p < 0.05 vs. NAC-untreated US + 5-FU
group), indicating that US + 5-FU could effectively en-
hance ROS generation. This increased ROS generation
was not due to the sonochemical effect because the 5-
FU was not a sonosensitizer, but due to the much in-
creased 5-FU uptake with the help of low intensity
ultrasound. The ROS was primarily generated inside
the cells.
Low-intensity ultrasound combined with 5-FU induced
DNA damage and ROS-mediated cell death
The results of the comet assays showed that 5-FU alone
(12.4 ± 2.2 %) could induce DNA damage at 24 h com-
pared with the Control and US groups (4.5 ± 1.3 and
6.2 ± 1.7 %, respectively; Fig. 3a). But more comets were
detected in US + 5-FU group (22.6 ± 3.4 %; p < 0.05), in-
dicating that low-intensity ultrasound combined with
5-FU synergistically increased the DNA damage.
To investigate the anti-tumor efficacy of US + 5-FU in
vitro, we determined the suitable dosage of 5-FU. After
48 h of 5-FU administration, there was a dosage-
dependent decrease in BEL-7402 cells (Additional file 1:
Figure S1a). The 5-FU dose of 10 μg/ml was recom-
mended for further experiments because it has a slight
anticancer effect but not good enough. As shown in
Fig. 3b, US + 5-FU significantly inhibited the growth of
BEL-7402, Hep G2, and HuH-7 at 48 h after the treat-
ment (with the inhibition ratios of 54.5 ± 4.6, 41.8 ± 3.3,
and 36.5 ± 5.6 %, respectively; p < 0.05 vs. other three
groups), whereas the effects of US or 5-FU alone only
produced the slight inhibition ratios of 7.6 ± 4.8 and
14.5 ± 8.3 % in BEL-7402, 12.3 ± 7.8 and 18.8 ± 5.9 % in
Hep G2, 10.6 ± 3.8 and 17.4 ± 5.3 % in HuH-7.
To see if the increased ROS accounts for the signifi-
cantly enhanced anticancer effects after the US + 5-FU
treatment, we further investigated the influence of ROS
on BEL-7402 cell viability. As shown in Fig. 3c, when
treated with the ROS scavenger NAC, cell viability in
US + 5-FU group was indeed partly rescued (an increase
of 24.7 ± 5.3 %; p < 0.05) compared with the group not
treated by the NAC. These data suggested that US + 5-
FU treatment exhibited anti-tumor effects by increasing
5-FU uptake and 5-FU-mediated ROS generation.
Low-intensity ultrasound combined with 5-FU triggered
the collapse of mitochondrial membrane potential via
ROS
To investigate the relationship among US + 5-FU, ROS
and mitochondria damage, we examined potential
changes of mitochondrial membrane potential (Δψm) in
BEL-7402 cells. As shown in Fig. 4a, b, compared with
the Control group, the relative Δψm in the US or 5-FU
alone groups was decreased by 25–30 %, while that of
the US + 5-FU group was further decreased by as much
Fig. 2 The uptake of 5-FU and 5-FU-mediated ROS production after the application of ultrasound. a Relative cumulative amounts of 5-FU in the
5-FU alone and US + 5-FU groups in BEL-7402 cells (★p < 0.05 vs. 5-FU group). b Representative intracellular ROS (green fluorescence) after the
treatment. c The relative level of intracellular ROS by the fluorescent intensity quantified with IOD values. Data was presented as the mean ± SD
(n = 6, ★p < 0.05 vs. other three groups; ★★p < 0.05 NAC-treated vs. NAC-untreated US + 5-FU group)
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as 96.9 ± 13.5 % (p < 0.05 vs. other three NAC-untreated
groups). When treated with NAC, the relative Δψm in
the US + 5-FU group was increased by 10-fold compared
with the NAC-untreated one (p < 0.05). These results
suggested that the US + 5-FU-mediated ROS treatment
was mainly responsible for the collapse of mitochondrial
membrane potential.
Low-intensity ultrasound combined with 5-FU activated
mitochondria-caspase pathway via ROS
To further examine how ROS was involved in US + 5-
FU-mediated cell apoptosis, we evaluated the influence
of both ROS and apoptosis-related proteins on the
mitochondria-caspase pathway in BEL-7402 cells. As
shown in Fig. 5a, a diffused red fluorescence was ob-
served indicating the translocation of cytochrome c
from mitochondria to the cytosol after the US + 5-FU
treatment (long arrow), but there were no obvious
changes in the Control and NAC-treated US +5-FU
groups (short arrow). These data indicated that ROS
was involved in the release of cytochrome c.
We also evaluated the change of apoptosis-related
proteins both in vitro and in vivo. The immunochemi-
cal staining results in vivo (Fig. 5b and Additional file
2: Figure S2a-d) revealed that the levels of p53, Bax and
cleaved caspase-3 proteins in the US + 5-FU group were
much higher compared with that of the Control group
(286.3 ± 15.3, 440.2 ± 31.8, and 591.4 ± 42.2 %, respectively;
p < 0.05 vs. other three groups), whereas the levels of Bcl-2
were lower (52.7 ± 9.2 %; p < 0.05 vs. the other three
groups). The alterations of p53, Bax, cleaved caspase-3 and
Bcl-2 protein expression was also observed in the US + 5-
Fig. 3 The DNA damage and cell viability after the treatment of low-intensity ultrasound combined with 5-FU. a DNA damage was evaluated by the
tail moment. b Cell viability in the BEL-7402, Hep G2, and HuH-7. c Cell viability in the Control, US, 5-FU, and US + 5-FU groups with and without NAC.
Data was presented as the mean ± SD (n = 6, ★p < 0.05 vs. other three groups; ★★p < 0.05 NAC-treated vs. NAC-untreated US + 5-FU group)
Fig. 4 Alteration of mitochondrial membrane potential by the treatment of low-intensity ultrasound combined with 5-FU. a Representative
mitochondrial membrane potential (Δψm) in BEL-7402 cells after the treatment. b The relative level of Δψm by the fluorescent intensity quantified with
IOD values. Data was presented as the mean ± SD (n = 6, ★p < 0.05 vs. other three groups; ★★p < 0.05 NAC-treated vs. NAC-untreated US + 5-FU group)
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FU group of BEL-7402 cells (Fig. 5c). When treated with
NAC, the expression of these proteins was recovered
(Fig. 5d), indicating that the combined US + 5-FU treat-
ment indeed regulated the expressions of apoptosis-related
proteins via ROS.
We further investigated the role of the US + 5-FU
treatment in cell apoptosis by treating BEL-7402 cells
with the ROS scavenger NAC or pan-caspase inhibitor
Z-VAD-FMK. As shown in Fig. 6, US + 5-FU exhibited
23.7 % apoptosis index, which was significantly higher
compared with the Control (3.4 %), US (8.5 %), and 5-
FU groups (10.6 %), while the NAC or Z-VAD-FMK
showed the potential to significantly reduce the apop-
tosis induced by the US + 5-FU treatment to 8.0 and
6.5 %, respectively. Meanwhile, the ratios of necrotic
cells in the NAC-treated (4.6 %) or Z-VAD-FMK-treated
group (4.1 %) were also reduced compared with the 8.1 %
of the US + 5-FU group. These data demonstrated that the
US + 5-FU treatment indeed induced caspase-dependent
apoptosis via ROS.
Low-intensity ultrasound combined with 5-FU exhibited
significant anti-tumor effects
We evaluated the suitable dosage of 5-FU for the in vivo
mice experiments. The administration of 5-FU resulted
in some anti-tumor effects but not an effective retard-
ation of tumor growth compared with the untreated
control mice (p < 0.05; Additional file 1: Figure S1b).
The 5-FU dose of 10 mg/kg was selected for further
experiments. Treatment with US or 5-FU alone led to
some degree of anti-tumor effect (with the inhibition
ratios of 27.7 ± 4.1 and 38.2 ± 5.5 %, respectively) after
17 days (Fig. 7a), but for US + 5-FU treatment, a signifi-
cant inhibition of tumor growth (inhibition ratio of
65.3 ± 3.8 %; p < 0.05) was observed compared with the
Control group.
Fig. 5 Activation of mitochondrial-caspase pathway of apoptosis by low-intensity ultrasound combined with 5-FU. a Representative fluorescence
images of the translocation of cytochrome c in BEL-7402 cells. Cytochrome c in NAC-untreated US + 5-FU group diffused in the cytosol (long
arrow), which was anchored to the mitochondria in the Control and NAC-treated US + 5-FU groups (short arrow). Representative expression of
apoptosis-related proteins in vivo (b) and in vitro (c) after the treatment. d Representative expression of apoptosis-related proteins with and without
NAC in BEL-7402 cells. Data was presented as the mean ± SD (n = 6, ★p < 0.05 vs. other three groups)
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We further evaluated the overall survival of BEL-7402
HCC-bearing nude mice. The results were given in a
Kaplan-Meier graph (Fig. 7b). The US + 5-FU group me-
diated a prolonged median survival of 30 days compared
to the 5-FU group (26 days), US group (25 days), and
Control group (23 days only). More detailed data are
given in Table 1. The log-rank test revealed a 30 % in-
crease in median survival after the US + 5-FU treatment
compared with the Control group (p = 0.001) and a
15 % increase compared with the 5-FU alone treated
group (p = 0.030). These data suggested that US + 5-FU
indeed induced significant anti-HCC effects.
In addition, H&E staining revealed a reduction in
hyperemia, necrosis and the number of small vessels
decreased in the US + 5-FU group compared with other
three groups (Fig. 7c). Then we further assessed cell apop-
tosis and proliferation after the US + 5-FU treatment. The
data in Fig. 7d showed that US + 5-FU exhibited a
Fig. 6 Induction of the caspase-dependent apoptosis by low-intensity ultrasound combined with 5-FU. Effects of NAC and Z-VAD-FMK on BEL-7402
cell apoptosis were determined by the Annexin V-PI assay
Table 1 Detailed results of the survival experiment in the BEL-7402 model




Control (n = 6) 26 23 – 23.8 ± 0.6 –
US (n = 6) 29 24 8.7 25.5 ± 0.9 0.141
5-FU (n = 6) 31 24 13.0 26.8 ± 1.1 0.030
US + 5-FU (n = 6) 35 26 29.8 30.8 ± 1.3 0.001
IST = Improvement in survival compared with the untreated control group
aCompared to the untreated control group. Mean survival = means ± SD
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significant difference in apoptosis index (AI), i.e.,
82.4 ± 5.2 % (p < 0.05) compared with the Control group,
while treatment with US or 5-FU alone induced less than
half of the apoptosis level. We also found that the PCNA
staining intensities had significantly decreased in the US +
5-FU group (37.2 ± 5.3 %; p < 0.05 vs. other three groups),
but there was much higher intensities of cell staining in
the Control, US, and 5-FU groups (Fig. 7e).
Discussion
Hepatocellular carcinoma is one of the most invasive
and lethal tumors that responds poorly to chemotherapy.
Therefore, there is an urgent need to find effective
clinical treatments for HCC. In this work, we designed
and constructed a low-intensity US device, aiming to
explore the efficacy and mechanisms responsible for
the enhancement of combined US + 5-FU treatment
for HCC.
It was reported that US can promote the delivery of
anticancer drugs into tumors [7, 19]. There were at least
three possible mechanisms by which US could increase
the permeability of the plasma membrane: heating effect,
cavitation effect, and direct mechanical force [20]. The
heat and cavitation effects were generally considered
responsible for the US bio-effects [21]. However, in our
experiment, we observed only a negligible temperature
rise after the application of low-intensity US (1.1 MHz,
1 W/cm2, 10 % duty cycle), indicating that the heat effect
was not the key mechanism here, consistent with the re-
port from Chumakova et al. [22]. Our previous study had
demonstrated that the main mechanism of low-intensity
US combined with chemotherapy drug scutellarin was
mechanical effect, which allowed drugs to be delivered to
cancer cells by increasing the frequency and contact area
between the drug and cells [13]. Herein, we found that
low-intensity US could temporarily “open” cell mem-
branes (Additional file 3: Figure S3) [23] and significantly
increased the uptake of 5-FU by as much as 7-fold in
BEL-7402 cells (Fig. 2a). More importantly, 5-FU-
mediated ROS production increased more than 14-
fold (Fig. 2b, c), which indicated that the mechanical
effect might not be the only mechanism here although
5-FU was not a sonosensitizer. Sundaram et al. reported
that the key mechanism of ultrasound-enhanced chemo-
therapy might be due to cavitation-generated ROS pro-
duction [24]. We therefore hypothesized that the main
Fig. 7 The anti-tumor effects on HCC after the treatment of low-intensity ultrasound combined with 5-FU. a Tumor-bearing nude mice in the Control, US
alone, 5-FU alone, and US + 5-FU groups. b Overall survival analysis results by the Kaplan-Meier survival curves (log-rank test, p= 0.001). c Representative
histopathological changes in the Control, US alone, 5-FU alone, and US + 5-FU groups. Representative TUNEL-positive (d) and PCNA-positive (e) cells from
mice of different treatment groups. The apoptotic index (AI) and relative cell proliferation were calculated as the number of positive cells for each group.
Data was presented as the mean ± SD (n= 6, ★p< 0.05 vs. other three groups)
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underlying mechanism of low-intensity US combined with
5-FU could well be the combination of mechanical and
cavitation effects.
ROS are a class of strong oxidant, which can regulate
many signal transduction pathways by directly reacting
with proteins, transcription factors and genes to modulate
their functions [25]. Emerging evidence showed that ex-
cessive levels of ROS stress might be one of the major
causes that triggered the apoptosis of SDT-treated cells
[26, 27]. It was reported that 5-FU-mediated ROS contrib-
uted to the upregulation of p53 and played a vital role
through the induction of apoptosis [17]. Depending on
the cellular context and the nature of the DNA damage,
5-FU-mediated p53 had the potential to further trigger
the apoptosis signaling pathway through the induction of
pro-apoptotic factor-Bax, and the downregulation of anti-
apoptotic factor-Bcl-2 [22, 28]. Bax mediated mitochon-
drial outer membrane permeabilization and regulated
cytochrome c release from mitochondria [29]. Subse-
quently, cytochrome c associated with procaspase-9/
Apaf-1 activated effector caspase-3 to initiate the
mitochondria-caspase pathway, thus inducing cellular
apoptosis [30]. Through the in vitro and in vivo evi-
dence (Fig. 5b, c), we confirmed that the increased
ROS enhanced the expressions of p53 protein and
found that the protein level of Bcl-2 was significantly
down-regulated, while Bax and cleaved caspase-3 pro-
tein expressions increased in the US + 5-FU treatment
group cells. Compared with the Control, US, and 5-FU
groups, the mitochondrial membrane potential in the US +
5-FU group was severely suppressed (Fig. 4a, b) and there
was an obvious translocation of cytochrome c from mito-
chondria into the cytoplasm after the US + 5-FU treatment
(Fig. 5a). The elevation of ROS production and the activa-
tion of apoptosis-related proteins further motivated the
mitochondria-caspase pathway and ultimately led to cell
apoptosis. This enhanced cell apoptosis could be partially
rescued by the ROS scavenger NAC or pan-caspase in-
hibitor Z-VAD-FMK (Fig. 6). Thus, we believed that the
increased ROS production triggered by the US + 5-FU
treatment was the main effector that caused the in-
creased tumor cell apoptosis.
In previous reports, p53 was proven to elevate ROS pro-
duction by activating ROS-generating proteins [31, 32].
Herein, we verified that ROS could indeed induce p53
expressions. However, it was not clear whether p53 also
induced ROS generation and related priorities. Interest-
ingly, p53 was shown to decrease ROS by regulating the
expression of antioxidant proteins in some reports
[33, 34]. It was also noted that low levels of H2O2 acti-
vated the tumor suppressor p53 to produce an antioxi-
dant response, but high levels of H2O2 might cause
p53-dependent apoptosis [35]. Therefore, we specu-
lated that if the increase of ROS reached a certain
threshold level that overwhelmed the antioxidant cap-
acity of cancer cells, ROS might exert a cytotoxic ef-
fect, leading to oxidative damage to malignant cells,
thus limiting cancer progression [36].
Interestingly, we found that the antioxidant NAC,
which was a ROS scavenger, could not completely eliminate
ROS production. This implied that there were different
kinds of ROS, some of them were not responsive to NAC.
Paradoxically, Chinery et al. found that antioxidants
pyrrolidinedithiocarbamate and vitamin E enhanced 5-
FU-mediated anti-tumor effects in colorectal cancer [37],
while the antioxidant NAC had the opposite effects in our
study. Possible explanation was that NAC might enhance
chemotherapy in p53-dependent manner.
In addition, as described by Yu et al. [38], there was
no denying that ultrasound enhanced the action of drugs
in most preclinical trials, but the improvement was dem-
onstrated in only limited clinical trials. This implied that
the efficacy of ultrasonic chemotherapy could depend on
the drugs, cell type, and tumor microenvironment so on.
Inappropriate experimental methods could also lead to
biases in preclinical trials. Maybe the data in an ectopic
model had poor clinical relevancy compared with in an
orthotopic model. The use of ultrasonic chemotherapy
for clinical application should be improved by optimiz-
ing the methods such as the sequence and interval of
drug administration or insonation in some cancer types.
Anyway, our study could provide feedback for preclinical
and translational medicine in ultrasonic chemotherapy.
Conclusions
In conclusion, we have studied the efficacy and mechanism
of US + 5-FU treatment on hepatocellular carcinoma. Our
results indicated that the primary mechanism for the much
enhanced anticancer effect was via the increased ROS pro-
duction, which triggered the mitochondria-caspase pathway
of apoptosis. It should be noted that low-intensity US com-
bined with 5-FU treated nude mice survived 30 % longer
than the untreated Control group and more than 15 % lon-
ger than the 5-FU alone group, which was significant. Our
results suggested that properly controlled low-intensity US
could greatly enhance the localized anticancer effect of 5-
FU. In a more general sense, the combined US +Chemo-
therapy-Drug treatment might offer an innovative way to
effectively reduce the drug dosage so as to minimize side ef-
fects of conventional chemotherapy.
Additional files
Additional file 1: Selection of suitable dosages of 5-FU. Figure S1.Selec-
tion of suitable dosages of 5-FU in vitro and in vivo. Cell viability (a) with
5-FU (0, 2, 5, 10, 20, 40, 60, 80, and 100 μg/ml) and tumor-bearing nude
mice (b) in the Control and
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5-FU-treated (5, 10, and 20 mg/kg) groups. Data was represented as the
mean ± SD (n = 6, ★p < 0.05 vs. Control group). (TIF 793 kb)
Additional file 2: Activation of apoptosis-related proteins by low-
intensity ultrasound combined with 5-FU. Figure S2. Activation of
apoptosis-related proteins by low-intensity ultrasound combined with 5-
FU in vivo. Protein levels of p53 (a), Bcl-2 (b), Bax (c) and cleaved caspase-
3 (d) were evaluated by immunohistochemisty in the Control, US, 5-FU,
and US + 5-FU groups. (TIF 8284 kb)
Additional file 3: SEM-imgaes of BEL-7402 cells exposed to low-
intensity ultrasound. Figure S3. SEM-imgaes of BEL-7402 cells exposed to
low-intensity ultrasound. The cells were treated without ultrasound (a) and
with ultrasound (b). The white arrows pointed out some sonoporation
pores. (TIF 1542 kb)
Abbreviations
5-FU: 5-fluorouracil; H&E staining: hematoxylin and eosin staining;
HCC: hepatocellular carcinoma; HPLC: high-performance liquid chromatography;
NAC: N-acetylcysteine; PCNA: proliferation cell nuclear antigen; ROS: reactive
oxygen species; SDT: sonodynamic therapy; TUNEL: terminal deoxynucleotidyl
transferase-mediated dutp nick end-labeling; US: ultrasound; US + 5-
FU: low-intensity ultrasound combined with 5-fluorouracil.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HZ and GL contributed equally to this work. HZ and WC designed the
experiment. HZ and GL conducted the experiment,analyzed the data, and
prepared the manuscript. YL, EL, HL, QZ, and BY supervised the study and
contributed in the manuscript revision. All authors read and approved the
final manuscript.
Acknowledgements
This work was supported by grants from the National Basic Research
Program of China (Grant No.2013CB632900), the National Key Technology
R&D Program of China (Grant No.2013BAI03B06), the National Natural
Science Foundation of China (Grant No.81502644), the Fundamental
Research Funds for the Central Universities (Grant No. HIT.NSRIF.2014066),
and the China Postdoctoral Science Foundation (Grant No.2014 M561341).
Author details
1Laboratory of Sono- and Photo-theranostic Technologies, Harbin Institute of
Technology, Harbin 150080, China. 2Department of Biochemistry and
Molecular Biology, Harbin Medical University, Harbin 150086, China.
3Department of Mathematics, and Materials Research Institute, The
Pennsylvania State University, University Park 16802, PA, USA.
Received: 26 January 2016 Accepted: 17 April 2016
References
1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al.
Global surveillance of cancer survival 1995–2009: analysis of individual
data for 25 676 887 patients from 279 population-based registries in 67
countries (CONCORD-2). Lancet. 2015;385:977–1010.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.
Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
3. Scudellari M. Drug development: try and try again. Nature. 2014;516:S4–6.
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action
and clinical strategies. Nat Rev Cancer. 2003;3:330–8.
5. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized,
multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin
versus doxorubicin as palliative chemotherapy in patients with advanced
hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–8.
6. McHale AP, Callan JF, Nomikou N, Fowley C, Callan B. Sonodynamic therapy:
concept, mechanism and application to cancer treatment. Adv Exp Med
Biol. 2016;880:429–50.
7. Trendowski M. The promise of sonodynamic therapy. Cancer Metastasis Rev.
2014;33(1):143–60.
8. Yu T, Wang Z, Mason TJ. A review of research into the uses of low level
ultrasound in cancer therapy. Ultrason Sonochem. 2004;11:95–103.
9. Tinkov S, Coester C, Serba S, Geis NA, Katus HA, Winter G, et al. New
doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy:
in-vivo characterization. J Control Release. 2010;148:368–72.
10. Todorova M, Agache V, Mortazavi O, Chen B, Karshafian R, Hynynen K, et al.
Antitumor effects of combining metronomic chemotherapy with the
antivascular action of ultrasound stimulated microbubbles. Int J Cancer.
2013;132:2956–66.
11. Goertz DE, Todorova M, Mortazavi O, Agache V, Chen B, Karshafian R, et al.
Antitumor effects of combining docetaxel (taxotere) with the antivascular
action of ultrasound stimulated microbubbles. PLoS One. 2012;7, e52307.
12. Yu T, Yang Y, Liu S, Yu H. Ultrasound increases DNA damage attributable to
cisplatin in cisplatin-resistant human ovarian cancer cells. Ultrasound Obstet
Gynecol. 2009;33:355–9.
13. Li H, Fan H, Wang Z, Zheng J, Cao W. Potentiation of scutellarin on
human tongue carcinoma xenograft by low-intensity ultrasound. PLoS
One. 2013;8, e59473.
14. He H, Huang H, Yu T. Detection of DNA damage in sonochemotherapy
against cisplatin-resistant human ovarian cancer cells using the modified
comet assay. Int J Radiat Biol. 2014;90:897–902.
15. Hu Z, Fan H, Lv G, Zhou Q, Yang B, Zheng J, et al. 5-aminolevulinic acid-mediated
sonodynamic therapy induces anti-tumor effects in malignant melanoma via
p53-miR-34a-Sirt1 axis. J Dermatol Sci. 2015;79:155–62.
16. Fan HX, Li HX, Chen D, Gao ZX, Zheng JH. Changes in the expression of
MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell
carcinoma: relationships and prognostic implications. J Exp Clin Cancer Res.
2012;31:90.
17. Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, et al. Ferredoxin
reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in
colorectal cancer cells. Nat Med. 2001;7:1111–7.
18. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, et al.
5-fluorouracil induces apoptosis in rat cardiocytes through intracellular
oxidative stress. J Exp Clin Cancer Res. 2012;31:60.
19. Wood AK, Sehgal CM. A review of Low-intensity ultrasound for cancer therapy.
Ultrasound Med Biol. 2015;41:905–28.
20. Dalecki D. Mechanical bioeffects of ultrasound. Annu Rev Biomed Eng. 2004;
6:229–48.
21. Mohamed MM, Mohamed MA, Fikry NM. Enhancement of antitumor effects
of 5-fluorouracil combined with ultrasound on Ehrlich ascites tumor in vivo.
Ultrasound Med Biol. 2003;29:1635–43.
22. Chumakova OV, Liopo AV, Evers BM, Esenaliev RO. Effect of 5-fluorouracil,
optison and ultrasound on MCF-7 cell viability. Ultrasound Med Biol. 2006;
32:751–8.
23. Lentacker I, De Cock I, Deckers R, De Smedt SC, Moonen CT. Understanding
ultrasound induced sonoporation: definitions and underlying mechanisms.
Adv Drug Deliv Rev. 2014;72:49–64.
24. Sundaram J, Mellein BR, Mitragotri S. An experimental and theoretical analysis
of ultrasound-induced permeabilization of cell membranes. Biophys J. 2003;84:
3087–101.
25. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-
mediated mechanisms: a radical therapeutic approach? Nat Rev Drug
Discov. 2009;8:579–91.
26. Yumita N, Iwase Y, Nishi K, Komatsu H, Takeda K, Onodera K, et al.
Involvement of reactive oxygen species in sonodynamically induced
apoptosis using a novel porphyrin derivative. Theranostics.
2012;2:880–8.
27. Yumita N, Okudaira K, Momose Y, Umemura S. Sonodynamically
induced apoptosis and active oxygen generation by gallium-porphyrin
complex, ATX-70. Cancer Chemother Pharmacol. 2010;66:1071–8.
28. Wang JM, Xiao BL, Zheng JW, Chen HB, Zou SQ. Effect of targeted magnetic
nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in
nude mice with transplanted human liver cancer. World J Gastroenterol.
2007;13:3171–5.
29. Borralho PM, da Silva IB M, Aranha MM, Albuquerque C, Nobre Leitao
C, Steer CJ, et al. Inhibition of Fas expression by RNAi modulates 5-
fluorouracil-induced apoptosis in HCT116 cells expressing wild-type
p53. Biochim Biophys Acta. 2007;1772:40–7.
30. Adachi Y, Taketani S, Oyaizu H, Ikebukuro K, Tokunaga R, Ikehara S. Apoptosis of
colorectal adenocarcinoma induced by 5-FU and/or
IFN-gamma through caspase 3 and caspase 8. Int J Oncol. 1999;15:1191–6.
Hu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:71 Page 11 of 12
31. Donald SP, Sun XY, Hu CA, Yu J, Mei JM, Valle D, et al. Proline oxidase, encoded
by p53-induced gene-6, catalyzes the generation of proline-dependent reactive
oxygen species. Cancer Res. 2001;61:1810–5.
32. Rivera A, Maxwell SA. The p53-induced gene-6 (proline oxidase) mediates
apoptosis through a calcineurin-dependent pathway. J Biol Chem. 2005;280:
29346–54.
33. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al.
TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;
126:107–20.
34. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE,
Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat
Med. 2005;11:1306–13.
35. D'Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that
generate specificity in ROS homeostasis. Nat Rev Mol Cell Bio. 2007;8:813–24.
36. Chen G, Wang F, Trachootham D, Huang P. Preferential killing of cancer
cells with mitochondrial dysfunction by natural compounds. Mitochondrion.
2010;10:614–25.
37. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ.
Antioxidants enhance the cytotoxicity of chemotherapeutic agents in
colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via
C/EBPbeta. Nat Med. 1997;3:1233–41.
38. Yu T, Luo L, Wang L. Ultrasound as a cancer chemotherapy sensitizer: the gap
between laboratory and bedside. Expert Opin Drug Deliv. 2016;13:37–47.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:71 Page 12 of 12
